The city of Durham, North Carolina, currently has 38 active clinical trials seeking participants for Lung Cancer research studies.
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Recruiting
This is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer). Nivolumab (Opdivo™) and ipilimumab (Yervoy™) are immunotherapy-type drugs which are approved for the treatment of advanced lung cancer that has expression of PD-L1 greater than or equal to 1%. Evolucumab is being combined with nivolumab and ipilimumab to see if it will improve the anti-tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: Duke Univ. Medical Center, Durham, North Carolina
Conditions: Lung Cancer Metastatic
Screening for High Frequency Malignant Disease
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Durham VA Medical Center, Durham, North Carolina
Conditions: Lung Cancer